Geode Capital Management, LLC Fate Therapeutics Inc Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,258,246 shares of FATE stock, worth $5.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,258,246

Previous 2,247,383 0.48%

Holding current value

$5.17 Million

Previous $7.37 Million 7.22%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.12 - $5.57 $33,892 - $60,506	10,863 Added 0.48%	2,258,246 $7.9 Million
Q2 2024 Aug 09, 2024	BUY	$3.26 - $7.08 $1.11 Million - $2.42 Million	341,400 Added 17.91%	2,247,383 $7.37 Million
Q1 2024 May 13, 2024	BUY	$3.54 - $8.35 $150,442 - $354,858	42,498 Added 2.28%	1,905,983 $14 Million
Q4 2023 Feb 13, 2024	BUY	$1.65 - $3.94 $145,432 - $347,275	88,141 Added 4.96%	1,863,485 $6.97 Million
Q3 2023 Nov 13, 2023	BUY	$2.02 - $5.04 $61,068 - $152,369	30,232 Added 1.73%	1,775,344 $3.76 Million
Q2 2023 Aug 11, 2023	BUY	$4.76 - $6.59 $630,809 - $873,326	132,523 Added 8.22%	1,745,112 $8.31 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $204,783 - $537,073	48,298 Added 3.09%	1,612,589 $9.19 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $637,064 - $1.54 Million	64,611 Added 4.31%	1,564,291 $15.8 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $715,402 - $1.23 Million	34,002 Added 2.32%	1,499,680 $33.6 Million
Q2 2022 Aug 12, 2022	SELL	$17.78 - $42.39 $152,001 - $362,392	-8,549 Reduced 0.58%	1,465,678 $36.3 Million
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $1.43 Million - $2.91 Million	48,259 Added 3.38%	1,474,227 $57.2 Million
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $1.05 Million - $1.41 Million	21,872 Added 1.56%	1,425,968 $83.4 Million
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $848,153 - $1.37 Million	-14,310 Reduced 1.01%	1,404,096 $83.2 Million
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $4.65 Million - $6.39 Million	69,094 Added 5.12%	1,418,406 $123 Million
Q1 2021 May 12, 2021	BUY	$72.16 - $117.4 $13.7 Million - $22.3 Million	189,798 Added 16.37%	1,349,312 $111 Million
Q4 2020 Feb 12, 2021	BUY	$38.09 - $100.95 $2.13 Million - $5.66 Million	56,024 Added 5.08%	1,159,514 $105 Million
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $2.19 Million - $2.92 Million	72,164 Added 7.0%	1,103,490 $44.1 Million
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $1.67 Million - $2.91 Million	82,538 Added 8.7%	1,031,326 $35.4 Million
Q1 2020 May 14, 2020	BUY	$17.28 - $31.88 $1.24 Million - $2.29 Million	71,953 Added 8.21%	948,788 $21.1 Million
Q4 2019 Feb 13, 2020	BUY	$13.39 - $20.73 $861,003 - $1.33 Million	64,302 Added 7.91%	876,835 $17.2 Million
Q3 2019 Nov 12, 2019	BUY	$15.47 - $22.5 $148,202 - $215,550	9,580 Added 1.19%	812,533 $12.6 Million
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $188,600 - $246,956	12,082 Added 1.53%	802,953 $16.3 Million
Q1 2019 May 14, 2019	BUY	$13.15 - $18.71 $1.17 Million - $1.66 Million	88,692 Added 12.63%	790,871 $13.9 Million
Q4 2018 Feb 13, 2019	BUY	$11.48 - $16.98 $2.15 Million - $3.17 Million	186,927 Added 36.28%	702,179 $9.01 Million
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $545,352 - $1.02 Million	62,326 Added 13.76%	515,252 $8.39 Million
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $442,354 - $650,976	48,292 Added 11.93%	452,926 $5.14 Million
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $359,484 - $785,729	57,061 Added 16.42%	404,634 $3.95 Million
Q4 2017 Feb 13, 2018	BUY	$3.94 - $6.64 $177,859 - $299,742	45,142 Added 14.93%	347,573 $2.12 Million
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $325,907 - $540,254	125,349 Added 70.79%	302,431 $1.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	177,082	177,082 $573,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Fate Therapeutics Inc Transaction History